par Matheeussen, Veerle;Lambeir, Anne-Marie;Jungraithmayr, Wolfgang;Gomez Malaver, Nelson ;McEntee, Kathleen ;Van der Veken, Pieter;Scharpé, Simon;De Meester, Ingrid
Référence Clinica chimica acta, 413, 3-4, page (456-462)
Publication Publié, 2012
Référence Clinica chimica acta, 413, 3-4, page (456-462)
Publication Publié, 2012
Article révisé par les pairs
Résumé : | Dipeptidyl peptidase IV (DPPIV, DPP4) is a serine protease that releases N-terminal dipeptides. It is a validated drug target for type 2 diabetes and DPPIV inhibitors are currently evaluated for other therapeutic applications. Various assays are used for DPPIV activity measurements in biological samples. Highly sensitive methods are needed to measure also very low activities in inhibited samples. |